Sanofi Vaccines Added To $19.4 Million Defense Logistics Agency Pharmaceutical Contract

Sanofi Vaccines US, based in Swiftwater, Pennsylvania, has been added as an awardee to an existing Defense Logistics Agency multiple-award contract for pharmaceutical products, with an award value of $19.4 million.

The contract, identified as SPE2D0-27-D-0001, was issued under a pharmaceutical procurement solicitation originally awarded on November 15, 2016.

The update adds Sanofi Vaccines US to the pool of suppliers eligible to participate in the government procurement program.

The Defense Logistics Agency uses multiple-award contracting arrangements to establish sources of supply for products required by federal government customers.

These arrangements can support the procurement of pharmaceutical products through established contractual terms, allowing authorized government purchasers to obtain supplies as requirements develop.

Sanofi Vaccines US becomes an additional contractor under the existing procurement structure rather than receiving an entirely new solicitation.

The announced award value is $19,449,682.

The notice does not identify individual pharmaceutical products, delivery schedules, performance locations, or the amount of funding obligated at the time of the update.

Accordingly, the stated contract value should not be interpreted as an amount already spent or guaranteed to be ordered.

Pharmaceutical supply arrangements play an important role in federal medical logistics by providing contracting channels through which government healthcare organizations can purchase medical products.

Adding suppliers to an existing multiple-award program can also expand the number of companies available to meet procurement requirements.

The original solicitation is identified as SPE2D0-15-R-0002.

Defense Logistics Agency Troop Support in Philadelphia, Pennsylvania, serves as the contracting activity.

Sanofi Vaccines US operates in the pharmaceutical and vaccine industry, and its inclusion in the contract provides the company with an additional federal procurement opportunity.

The update reflects the continued administration of a long-running pharmaceutical supply agreement that supports government medical purchasing requirements.